Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00372905 | Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma | terminated | Phase 1 / Phase 2 | 18 | Northwestern UniversityOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT01090414 | An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study | terminated | Phase 1 / Phase 2 | 202 | Gilead SciencesINDUSTRY | 1 | Aug 28, 2019 | clinicaltrials |
| NCT01160354 | Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML) | terminated | Phase 1 / Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT01065805 | A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma | terminated | Phase 1 / Phase 2 | 94 | AHS Cancer Control AlbertaOTHER | 1 | Aug 22, 2019 | clinicaltrials |
| NCT00089284 | Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL | terminated | Phase 1 / Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT00949988 | A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia(BMS-CA180105) | terminated | Phase 1 / Phase 2 | 3 | University of California, San DiegoOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT02337478 | Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 2 | 5 | Wake Forest University Health SciencesOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT02535806 | Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults | terminated | Phase 2 | 2 | Children's Mercy Hospital Kansas CityOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT03547154 | Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026) | terminated | Phase 2 / Phase 3 | 344 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 12, 2019 | clinicaltrials |
| NCT02634827 | Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation | terminated | Phase 2 | 1 | Mayo ClinicOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT00167180 | Post Transplant Donor Lymphocyte Infusion | terminated | Phase 2 | 57 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT01875237 | Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene | terminated | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT02477787 | Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDS(DNKI-4) | terminated | Phase 2 | 77 | Asan Medical CenterOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT02160041 | BGJ398 for Patients With Tumors With FGFR Genetic Alterations(CBGJ398XUS04) | terminated | Phase 2 | 84 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 18, 2019 | clinicaltrials |
| NCT01853228 | A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 17 | Janssen Research & Development, LLCINDUSTRY | 7 | Jun 17, 2019 | clinicaltrials |
| NCT03333746 | Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 1 | Yvonne EfeberaOTHER | 1 | May 30, 2019 | clinicaltrials |
| NCT00290706 | A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 32 | Northwestern UniversityOTHER | 1 | May 28, 2019 | clinicaltrials |
| NCT02592876 | Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma | terminated | Phase 2 | 81 | Seagen Inc.INDUSTRY | 1 | May 17, 2019 | clinicaltrials |
| NCT02907073 | Positron Emission Tomography (PET) Imaging Studies With NIS Reporter | terminated | Phase 1 / Phase 2 | 8 | Mayo ClinicOTHER | 1 | May 17, 2019 | clinicaltrials |
| NCT02613182 | Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis(OLE) | terminated | Phase 2 | 34 | Prothena Biosciences Ltd.INDUSTRY | 1 | May 16, 2019 | clinicaltrials |
| NCT02421354 | Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis | terminated | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT02258529 | Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma | terminated | Phase 2 | 10 | Gilead SciencesINDUSTRY | 1 | May 14, 2019 | clinicaltrials |
| NCT02042950 | A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma | terminated | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | May 1, 2019 | clinicaltrials |
| NCT02568683 | Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) | terminated | Phase 1 / Phase 2 | 10 | Gilead SciencesINDUSTRY | 2 | Apr 17, 2019 | clinicaltrials |
| NCT00808080 | A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell (AHSC) Transplantation for Acute Myeloid Leukemia (AML)(AMLCTL) | terminated | Phase 1 / Phase 2 | 6 | Thomas A. Lane, MDOTHER | 1 | Apr 9, 2019 | clinicaltrials |
| NCT02030405 | Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 2 | 4 | Steven E. CoutreOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT02627573 | Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT | terminated | Phase 2 | 32 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT03381118 | Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients | terminated | Phase 2 | 16 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT02518750 | Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma | terminated | Phase 2 | 3 | St. Jude Children's Research HospitalOTHER | 1 | Apr 3, 2019 | clinicaltrials |
| NCT00801931 | Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders | terminated | Phase 1 / Phase 2 | 1 | Columbia UniversityOTHER | 1 | Mar 27, 2019 | clinicaltrials |
| NCT01116232 | Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation | terminated | Phase 2 | 4 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 26, 2019 | clinicaltrials |
| NCT02763254 | Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas(CIVIC) | terminated | Phase 2 | 1 | Cell Medica LtdINDUSTRY | 1 | Mar 26, 2019 | clinicaltrials |
| NCT03154047 | Study in Subjects With Light Chain (AL) Amyloidosis | terminated | Phase 2 | 80 | Prothena Biosciences Ltd.INDUSTRY | 10 | Mar 26, 2019 | clinicaltrials |
| NCT02418000 | A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations | terminated | Phase 1 / Phase 2 | 27 | Spirita Oncology, LLCINDUSTRY | 1 | Mar 20, 2019 | clinicaltrials |
| NCT01948180 | Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma(CITADEL) | terminated | Phase 2 | 15 | Cell Medica LtdINDUSTRY | 4 | Mar 13, 2019 | clinicaltrials |
| NCT02855359 | Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma | terminated | Phase 2 | 24 | Seagen Inc.INDUSTRY | 2 | Mar 11, 2019 | clinicaltrials |
| NCT00648739 | Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM | terminated | Phase 1 / Phase 2 | 26 | Alexion Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT00920556 | A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma | terminated | Phase 2 | 24 | Sirtris, a GSK CompanyINDUSTRY | 2 | Feb 27, 2019 | clinicaltrials |
| NCT01403246 | Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 1 / Phase 2 | 9 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT00655395 | Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine | terminated | Phase 1 / Phase 2 | 25 | Viron Therapeutics IncINDUSTRY | 1 | Jan 28, 2019 | clinicaltrials |
| NCT02145598 | Treatment Optimization in Patients With Untreated Multiple Myeloma(GERMAIN) | terminated | Phase 2 / Phase 3 | 85 | Dr. med. Lars-Olof MueggeOTHER | 1 | Jan 16, 2019 | clinicaltrials |
| NCT03218163 | MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma | terminated | Phase 2 | 1 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 14, 2019 | clinicaltrials |
| NCT01892293 | CT Antigen TCR-Engineered T Cells for Myeloma | terminated | Phase 1 / Phase 2 | 6 | AdaptimmuneINDUSTRY | 1 | Jan 10, 2019 | clinicaltrials |
| NCT02614560 | A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients | terminated | Phase 1 / Phase 2 | 14 | Seagen Inc.INDUSTRY | 1 | Jan 9, 2019 | clinicaltrials |
| NCT02730195 | Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia | terminated | Phase 2 | 9 | Emory UniversityOTHER | 1 | Jan 9, 2019 | clinicaltrials |
| NCT01303965 | Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM) | terminated | Phase 1 / Phase 2 | 14 | Sherif S. FaragOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT02008006 | BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT)(BENEFIT) | terminated | Phase 2 | 21 | Centre Leon BerardOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT00074490 | Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers | terminated | Phase 2 | 442 | National Cancer Institute (NCI)NIH | 1 | Dec 31, 2018 | clinicaltrials |
| NCT00667017 | RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma | terminated | Phase 2 | 1 | University of Texas Southwestern Medical CenterOTHER | 1 | Dec 14, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Sep 4, 2019source: clinicaltrials